Guilhaume Debroas, Ph.D.

Guilhaume Debroas, Ph.D. has worked for MaaT Pharma as the Head of Investor Relations since June 2023. Prior to this, they held multiple positions at Innate Pharma including Senior Project Manager, Corporate Strategy & Investor Relations and Corporate strategy & Investor Relations analyst from September 2020 to May 2023. Guilhaume also worked as the VP Entrepreneurship for ESSEC Life Sciences, a student organization focused on life sciences, from September 2019 to August 2020. Earlier in their career, they served as a Ph.D. student for Pr. Eric Vivier and Dr. Sophie Ugolini's team at CIML from October 2013 to September 2018. Their research focused on the regulation of the immune response of the skin by the sensory nervous system.

Guilhaume Debroas, Ph.D. completed a Licence de Biologie Cellulaire from Aix-Marseille University in 2011. Guilhaume then earned a Master's degree in Immunology from the same university in 2013. From 2013 to 2018, they pursued a Doctor of Philosophy degree in Biology, with a specialization in Neuro-Immunology, also from Aix-Marseille University. In 2019, they completed a Master's degree specializing in Strategy and Management of International Business from ESSEC Business School. Additionally, they obtained a certification in Negotiation Fundamentals from Coursera in September 2019.